3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Gastrointestinal
8
Genitourinary
7
Thoracic
6
Head & Neck
4
Endocrine
2
Breast
2
Sarcoma
1
NET
1
Dermatologic
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
lutetium Lu 177 dotatate
18
Everolimus
13
Temozolomide
12
Nivolumab
10
pembrolizumab
9
cabozantinib
8
Capecitabine
8
Sunitinib
7
lenvatinib
5
Magnetic Resonance Spectroscopy
5
Etoposide
5
lanreotide
4
gallium Ga 68 dotatate
4
Specimen Handling
4
Ipilimumab
4
Cisplatin
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
telotristat ethyl
3
surufatinib
3
pazopanib
3
avelumab
3
Octreotide
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Bevacizumab
3
sintilimab
2
fosbretabulin
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
zimberelimab
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled